RCUS

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Arcus Biosciences Inc

NYSE | RCUS

16.60

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$1.80B

Market Cap

-

P/E Ratio

-3.14

EPS

$18.98

52 Week High

$6.50

52 Week Low

HEALTHCARE

Sector

RCUS Chart

Recent Chart
Price Action

RCUS Technicals

Tags:

RCUS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $258M
Total Revenue $258M
Cost Of Revenue $10M
Costof Goods And Services Sold $10M
Operating Income -$330M
Selling General And Administrative $120M
Research And Development $448M
Operating Expenses $588M
Investment Income Net -
Net Interest Income $48M
Interest Income $52M
Interest Expense $4M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $10M
Income Before Tax -$283M
Income Tax Expense $1M
Interest And Debt Expense -
Net Income From Continuing Operations -$284M
Comprehensive Income Net Of Tax -
Ebit -$279M
Ebitda -$269M
Net Income -$283M

Revenue & Profitability

Earnings Performance

RCUS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.2B
Total Current Assets $1B
Cash And Cash Equivalents At Carrying Value $150M
Cash And Short Term Investments $150M
Inventory -
Current Net Receivables $25M
Total Non Current Assets $134M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $14M
Short Term Investments $828M
Other Current Assets $13M
Other Non Current Assets -
Total Liabilities $665M
Total Current Liabilities $226M
Current Accounts Payable $18M
Deferred Revenue -
Current Debt -
Short Term Debt $12M
Total Non Current Liabilities $439M
Capital Lease Obligations $12M
Long Term Debt $48M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $60M
Other Current Liabilities $110M
Other Non Current Liabilities $157M
Total Shareholder Equity $485M
Treasury Stock -
Retained Earnings -$1.1B
Common Stock $1.6B
Common Stock Shares Outstanding $90M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$170M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $10M
Capital Expenditures $6M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$84M
Cashflow From Financing $277M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$283M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $258M
Total Revenue $258M
Cost Of Revenue $10M
Costof Goods And Services Sold $10M
Operating Income -$330M
Selling General And Administrative $120M
Research And Development $448M
Operating Expenses $588M
Investment Income Net -
Net Interest Income $48M
Interest Income $52M
Interest Expense $4M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $10M
Income Before Tax -$283M
Income Tax Expense $1M
Interest And Debt Expense -
Net Income From Continuing Operations -$284M
Comprehensive Income Net Of Tax -
Ebit -$279M
Ebitda -$269M
Net Income -$283M

RCUS News

RCUS Profile

Arcus Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company headquartered in Hayward, California, dedicated to revolutionizing cancer treatment through its innovative pipeline of immune-oncology and targeted therapies. The company leverages proprietary platforms and strategic collaborations to develop cutting-edge therapies aimed at empowering the immune system to combat tumors. With a strong commitment to improving patient outcomes, Arcus is uniquely positioned for substantial growth as it advances its drug candidates through clinical trials and prepares for potential market entry, making it an attractive prospect for institutional investors focused on the biopharmaceutical sector.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
IVF
+85.67%
$1.40
NAYA
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.17%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
AADI
+24.28%
$2.61
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
BTG
+3.96%
$5.89
VSEE
-13.85%
$0.51
QS
-13.38%
$15.46
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
ABAT
-36.64%
$5.67
NAK
-4.34%
$2.64
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
BAC
-4.03%
$50.17
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.34%
$0.43
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-5.05%
$51.08
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
IVF
+85.67%
$1.40
NAYA
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.17%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
AADI
+24.28%
$2.61
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
BTG
+3.96%
$5.89
VSEE
-13.85%
$0.51
QS
-13.38%
$15.46
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
ABAT
-36.64%
$5.67
NAK
-4.34%
$2.64
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
BAC
-4.03%
$50.17
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.34%
$0.43
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-5.05%
$51.08
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.